Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

15.33 -2.36

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.51

Max

15.87

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+101.66% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-71M 1.3B
Ouverture précédente	17.69
Clôture précédente	15.33

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 juil. 2026, 23:51 UTC

Cryptocurrency market mixed as Bitcoin dips and Ethereum rises ahead of key U.S. inflation data releases impacting Federal Reserve policy.

12 juil. 2026, 23:51 UTC

Markets brace for key U.S. inflation and retail sales data releases, with potential implications for Federal Reserve policy amid ongoing economic pressures.

12 juil. 2026, 23:51 UTC

Cryptocurrency market shows mixed performance ahead of key U.S. inflation data, as Federal Reserve signals focus on AI in monetary policy.

12 juil. 2026, 23:51 UTC

Cryptocurrency market shows mixed performance ahead of critical U.S. economic data releases that may impact Federal Reserve monetary policy.

12 juil. 2026, 23:51 UTC

Bank of Korea Expected to Maintain Interest Rate at 2.5% Amid Rising Inflation and Economic Uncertainty

12 juil. 2026, 23:51 UTC

China's House Price Index YoY Release on July 15 Expected to Show Continued Decline Amidst Ongoing Property Sector Challenges and Global Economic Uncertainty.

12 juil. 2026, 23:41 UTC

US Import Prices Expected to Decrease by 0.4% Amid Cautious Market Sentiment and Geopolitical Tensions Ahead of Key Economic Data Releases

12 juil. 2026, 23:41 UTC

Housing Starts Data Release on July 17, 2026: Analysts Brace for Weakness Amid High Mortgage Rates and Economic Pressures.

12 juil. 2026, 23:41 UTC

US Export Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of Key Economic Data Releases

12 juil. 2026, 23:41 UTC

U.S. Building Permits MoM Prel for June 2026 Set to Release Amid Heightened Focus on Housing Trends and Legislative Changes

12 juil. 2026, 23:41 UTC

Upcoming U.S. Housing Starts Data Release on July 17 Expected to Influence Economic Outlook Amid Legislative Changes and Key Macroeconomic Indicators.

12 juil. 2026, 23:41 UTC

U.S. Building Permits Data Release on July 17 Expected to Show Annualized Rate of 1.42 Million Amid Cautious Market Sentiment and Key Macroeconomic Indicators Ahead.

12 juil. 2026, 23:41 UTC

Macro News

Correlated Moves

The US 30Y Treasury Bond Index is lower as capital shifts to technology sectors, with rising oil prices amid U.S.-Iran tensions impacting safe-haven demand.

12 juil. 2026, 23:31 UTC

Australia's NAB Business Confidence Index set for release amid cautious sentiment and global economic uncertainties.

12 juil. 2026, 23:21 UTC

Philadelphia Fed Manufacturing Index Release on July 16 Expected to Show Moderate Optimism Amidst Cautious Market Sentiment and Geopolitical Tensions.

12 juil. 2026, 23:21 UTC

U.S. Retail Sales Expected to Rise 0.3% in June Amid Cautious Optimism and Key Economic Indicators Ahead of Fed Policy Insights

12 juil. 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Decline 0.1% in June Amid Economic Caution and Geopolitical Tensions

12 juil. 2026, 23:11 UTC

Canada's housing starts data set for July 16, 2026, expected to show resilience with a forecast of 260K units amid positive government initiatives.

12 juil. 2026, 23:01 UTC

NZD/CHF has moved higher in after-market trading, currently 1.22% above its 20-day moving average. No specific news was identified for the price move.

12 juil. 2026, 23:01 UTC

Macro News

Correlated Moves

The U.S. dollar strengthens against major currencies, contributing to a modest after-hours gain in USD/CHF amid rising geopolitical tensions and a higher Dollar Index.

12 juil. 2026, 23:01 UTC

Macro News

Correlated Moves

GBP/USD is trading lower after the U.S. dollar strengthened against major currencies amid geopolitical tensions and anticipation of key macroeconomic data releases.

12 juil. 2026, 23:01 UTC

Macro News

The U.S. dollar rose today, reaching a two-day high against the euro amid geopolitical tensions with Iran affecting shipping route stability.

12 juil. 2026, 23:01 UTC

Market anticipates NY Empire State Manufacturing Index reading of 8.7 amid cautious sentiment ahead of key macroeconomic data releases.

12 juil. 2026, 23:01 UTC

Core PPI for June 2026 set to rise by 0.4% MoM, signaling cautious market sentiment ahead of key economic indicators and Federal Reserve insights.

12 juil. 2026, 23:01 UTC

Market Braces for July 15 PPI Release Amid Anticipated 0.2% Increase and Heightened Volatility from Geopolitical Tensions.

12 juil. 2026, 23:01 UTC

The EUR/HUF is trading higher after-market, reaching a session high earlier. Market focus remains on upcoming U.S. inflation data that may impact Fed policy.

12 juil. 2026, 23:01 UTC

Palladium is trading lower today, continuing a decline since Friday's close. Market focus remains on upcoming U.S. economic data releases.

12 juil. 2026, 23:01 UTC

Macro News

Correlated Moves

Gold prices are lower amid a stronger U.S. dollar and renewed U.S.-Iran military tensions, impacting market sentiment toward safe-haven assets.

12 juil. 2026, 23:01 UTC

EUR/NOK is trading lower in after-market hours, reflecting a decline since Friday's close. The price remains near the midpoint of its one-month range.

12 juil. 2026, 23:01 UTC

Macro News

Copper prices are lower as geopolitical tensions rise amid U.S.-Iran confrontations. Reports of Iraq's oil agreements may further impact market dynamics.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

101.66% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 101.66%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.